Arbocin Vet

Marbofloxacin has been effective for some blood-borne
pathogens such as Mycoplasma haemofelis in cats.

Avoid use in young animals because of risk of cartilage injury. Use cautiously in animals that may be prone to seizures.

Like other quinolones, marbofloxacin is labeled as contraindicated in small and medium breed dogs up to 8 months of age, large breeds to 12 months old,
and giant breeds to 18 months old. It is also labeled as contraindicated in cats under 12 months of age. Quinolones are also contraindicated in patients hypersensitive to them.
Marbofloxacin can (rarely) cause CNS stimulation and should be used with caution in patients with seizure disorders.
prohibited the use of this drug in food-producing animals.

Mode of Action: Marbofloxacin is a bactericidal agent. The bactericidal activity of marbofloxacin is concentration dependent, with susceptible bacteria cell death occurring within 20–30 minutes of exposure. Like other fluoroquinolones, marbofloxacin has demonstrated a significant post-antibiotic effect for both gram − and + bacteria and is active in both stationary and growth phases of bacterial replication. Its mechanism of action is not thoroughly understood, but it is believed to act by inhibiting bacterial DNA-gyrase (a type-II topoisomerase), preventing DNA supercoiling and DNA synthesis.

Pharmacoklinetics: In dogs, the half-life is 7–14 hours (overall oral average is 12.4 hours), with a volume of distribution (VD) of 1.5–2 L/kg. In horses, the half-life
has varied from 4.7–7.6 hours, depending on the study, with a VD of 1.5–2.8 L/kg. Oral absorption is close to 100% in small animals and approximately 60% in horses. In cattle, the half-lives are 5–9 hours in calves and 4–7 hours in ruminants. In preruminant calves, oral absorption is approximately 100%. In pigs, the half-life is 13–18 hours, with a VD of 1.6–1.75 L/kg, and oral absorption is 80%. In young pigs, the half-life is 13 hours.

ANTACIDS/DAIRY PRODUCTS: Containing cations (Mg++, Al+++, Ca++) may bind to marbofloxacin and prevent its absorption; separate doses of these products by at least 2 hours.
ANTIBIOTICS, OTHER (aminoglycosides, 3rd-generation cephalosporins, penicillins—extended-spectrum): Synergism may occur, but is not predictable, against some bacteria (particularly Pseudomonas aeruginosa) with these compounds. Although marbofloxacin has minimal activity against anaerobes, in vitro synergy has been reported when used
with clindamycin against strains of Peptostreptococcus, Lactobacillus and Bacteroides fragilis.
CYCLOSPORINE: Fluoroquinolones may exacerbate the nephrotoxicity and reduce the metabolism of cyclosporine (used systemically).
FLUNIXIN: Has been shown in dogs to increase the AUC and elimination half-life of enrofloxacin and enrofloxacin increases the AUC and elimination half-life of flunixin; it is unknown if marbofloxacin also causes this effect or if other NSAIDs interact with marbofloxacin in dogs.
GLYBURIDE: Severe hypoglycemia possible.
IRON, ZINC (oral): Decreased marbofloxacin absorption; separate doses by at least two hours
METHOTREXATE: Increased MTX levels possible with resultant toxicity.
NITROFURANTOIN: May antagonize the antimicrobial activity of the fluoroquinolones and their concomitant use is not recommended.
PHENYTOIN: Marbofloxacin may alter phenytoin levels.
PROBENECID: Blocks tubular secretion of ciprofloxacin and may also increase the blood level and half-life of marbofloxacin.
QUINIDINE: Increased risk for cardiotoxicity
SUCRALFATE: May inhibit absorption of marbofloxacin; separate doses of these drugs by at least 2 hours.
THEOPHYLLINE: Marbofloxacin may increase theophylline blood levels; this interaction is more likely with enrofloxacin than with marbofloxacin
WARFARIN: Potential for increased warfarin effects

With the exception of potential cartilage abnormalities in young animals, the adverse effect profile of marbofloxacin is
usually limited to GI distress (vomiting, anorexia, soft stools, diarrhea) and decreased activity.
Other fluoroquinolones have, in rare incidences, caused elevated hepatic enzymes, ataxia, seizures, depression, lethargy, and nervousness in dogs. Hypersensitivity reactions or crystalluria could potentially occur.

It is unlikely an acute overdose of marbofloxacin would result in signs more serious than either anorexia or vomiting.

Dogs receiving 55 mg/kg per day for 12 days developed anorexia, vomiting, dehydration, tremors, red skin, facial swelling, lethargy, and weight loss.

Meat: 6 days.

Milk: 1.5 day

Marbofloxacin should be stored below 30°C